A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD8154 Following Single and Multiple Ascending Dose Administration in Healthy Subjects
Latest Information Update: 17 Sep 2021
At a glance
- Drugs AZD-8154 (Primary) ; AZD-8154 (Primary)
- Indications Asthma
- Focus Adverse reactions; First in man
- Sponsors AstraZeneca
- 28 Jun 2021 Results published in the British Journal of Clinical Pharmacology
- 20 May 2020 Results presented at the 116th International Conference of the American Thoracic Society
- 07 Aug 2019 Status changed from active, no longer recruiting to completed.